Fig 1: Combination of VS‐4718 and GDC‐0449 in esophageal squamous cell carcinoma (ESCC) treatment in vivo. (A) KYSE510 (upper panel) or KYSE410 (lower panel) tumor‐beared mice with (right panel)/without (left panel) rhCCL22 were treated with VS‐4718 or GDC‐0449 and their combination. Curves of tumor volumes were shown. (B–D) The expression of Ki‐67 (B), CD31 (C), or LYVE1 (D) in indicated KYSE410 and KYSE510 tumors was evaluated using quantitative enzyme‐linked immunosorbent assay (ELISA) assays. Black bar: KYSE410 tumor, left panel of KYSE410 group: cont (without C‐C motif chemokine 22 [CCL22]), right panel of KYSE410 group: with CCL22; gray bar: KYSE510 tumor, left panel of KYSE510 group: cont (without CCL22), right panel of KYSE510 group: with CCL22; *p < 0.05; ***p < 0.001 as compared with the control cells. Error bars, mean ± SD of five independent experiments.
Supplier Page from RayBiotech for Human Ki-67/MKI67 ELISA